Common stock offered by us Shares of our common stock having an aggregate offering price of up to $25,000,000.Manner of Offering “At the market offerings” that may be made from time to time through our sales agent, JMP. See “Plan of Distribution” on page S-16 of this prospectus supplement.
Common stock to be outstanding
immediately after this offering
12,362,757 shares, assuming sales at a price of $8.30 per share, which was the last reported sale price of our common stock on February 12, 2020.Use of proceeds We currently intend to use the net proceeds from this offering for preparatory commercial activities for the potential commercial launch of IV meloxicam, pipeline development activities, and general corporate purposes. See “Use of Proceeds.”Risk Factors An investment in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement and page 7 of the accompanying prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus supplement.The Nasdaq Capital Market symbol BXRX
The number of shares of our common stock to be outstanding immediately after this offering is based on 9,350,709 shares of our common stock outstanding as of December 31, 2019, and excludes:
•
643,879 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2019 at a weighted- average exercise price of $6.33 per share;
•
1,380,030 shares of our common stock issuable upon the vesting and settlement of restricted stock units outstanding as of December 31, 2019; and
•
1,443,626 shares of our common stock available for future issuance as of December 31, 2019 under our 2019 Equity Incentive Plan.
News 
Market Data 
Discover 
